Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells

Yanghee Woo, Kaitlyn J. Kelly, Marianne M. Stanford, Charles Galanis, Yun Shin Chun, Yuman Fong, Douglas McFadden

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Viral oncolytic therapy, which seeks to exploit the use of live viruses to treat cancer, has shown promise in the treatment of cancers resistant to conventional anticancer therapies. Among the most difficult to treat cancers is advanced pancreatic adenocarcinoma. Our study investigates the ability of a novel oncolytic agent, myxoma virus, to infect, productively replicate in, and kill human pancreatic cancer cells in vitro. Methods: The myxoma virus vMyxgfp was tested against a panel of human pancreatic adenocarcinoma cell lines. Infectivity, viral proliferation, and tumor cell kill were assessed. Results: Infection of tumor cells was assessed by expression of the marker gene enhanced green fluorescent protein (e-GFP). vMyxgfp had the ability to infect all pancreatic cancer cell lines tested. Killing of tumor cells varied among the 6 cell lines tested, ranging from >90% cell kill at 7 days for the most sensitive Panc-1 cells, to 39% in the most resistant cell line Capan-2. Sensitivity correlated to replication of virus, and was found to maximally exhibit a four-log increase in foci-forming units for the most sensitive Panc-1 cells within 72 h. Conclusion: Our study demonstrates for the first time the ability of the myxoma virus to productively infect, replicate in, and lyse human pancreatic adenocarcinoma cells in vitro. These data encourage further investigation of this virus, which is pathogenic only in rabbits, for treatment of this nearly uniformly fatal cancer.

Original languageEnglish (US)
Pages (from-to)2329-2335
Number of pages7
JournalAnnals of Surgical Oncology
Volume15
Issue number8
DOIs
StatePublished - Aug 1 2008
Externally publishedYes

Fingerprint

Myxoma virus
Adenocarcinoma
Neoplasms
Cell Line
Pancreatic Neoplasms
Viruses
Virus Replication
Cell Proliferation
Rabbits
Gene Expression

Keywords

  • In vitro
  • Myxoma virus
  • Oncolytic therapy
  • Pancreatic cancer
  • Viral vectors

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Woo, Y., Kelly, K. J., Stanford, M. M., Galanis, C., Shin Chun, Y., Fong, Y., & McFadden, D. (2008). Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Annals of Surgical Oncology, 15(8), 2329-2335. https://doi.org/10.1245/s10434-008-9924-z

Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. / Woo, Yanghee; Kelly, Kaitlyn J.; Stanford, Marianne M.; Galanis, Charles; Shin Chun, Yun; Fong, Yuman; McFadden, Douglas.

In: Annals of Surgical Oncology, Vol. 15, No. 8, 01.08.2008, p. 2329-2335.

Research output: Contribution to journalArticle

Woo, Y, Kelly, KJ, Stanford, MM, Galanis, C, Shin Chun, Y, Fong, Y & McFadden, D 2008, 'Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells', Annals of Surgical Oncology, vol. 15, no. 8, pp. 2329-2335. https://doi.org/10.1245/s10434-008-9924-z
Woo Y, Kelly KJ, Stanford MM, Galanis C, Shin Chun Y, Fong Y et al. Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. Annals of Surgical Oncology. 2008 Aug 1;15(8):2329-2335. https://doi.org/10.1245/s10434-008-9924-z
Woo, Yanghee ; Kelly, Kaitlyn J. ; Stanford, Marianne M. ; Galanis, Charles ; Shin Chun, Yun ; Fong, Yuman ; McFadden, Douglas. / Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells. In: Annals of Surgical Oncology. 2008 ; Vol. 15, No. 8. pp. 2329-2335.
@article{7b2f11bd25714cd09f5709872b52427d,
title = "Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells",
abstract = "Background: Viral oncolytic therapy, which seeks to exploit the use of live viruses to treat cancer, has shown promise in the treatment of cancers resistant to conventional anticancer therapies. Among the most difficult to treat cancers is advanced pancreatic adenocarcinoma. Our study investigates the ability of a novel oncolytic agent, myxoma virus, to infect, productively replicate in, and kill human pancreatic cancer cells in vitro. Methods: The myxoma virus vMyxgfp was tested against a panel of human pancreatic adenocarcinoma cell lines. Infectivity, viral proliferation, and tumor cell kill were assessed. Results: Infection of tumor cells was assessed by expression of the marker gene enhanced green fluorescent protein (e-GFP). vMyxgfp had the ability to infect all pancreatic cancer cell lines tested. Killing of tumor cells varied among the 6 cell lines tested, ranging from >90{\%} cell kill at 7 days for the most sensitive Panc-1 cells, to 39{\%} in the most resistant cell line Capan-2. Sensitivity correlated to replication of virus, and was found to maximally exhibit a four-log increase in foci-forming units for the most sensitive Panc-1 cells within 72 h. Conclusion: Our study demonstrates for the first time the ability of the myxoma virus to productively infect, replicate in, and lyse human pancreatic adenocarcinoma cells in vitro. These data encourage further investigation of this virus, which is pathogenic only in rabbits, for treatment of this nearly uniformly fatal cancer.",
keywords = "In vitro, Myxoma virus, Oncolytic therapy, Pancreatic cancer, Viral vectors",
author = "Yanghee Woo and Kelly, {Kaitlyn J.} and Stanford, {Marianne M.} and Charles Galanis and {Shin Chun}, Yun and Yuman Fong and Douglas McFadden",
year = "2008",
month = "8",
day = "1",
doi = "10.1245/s10434-008-9924-z",
language = "English (US)",
volume = "15",
pages = "2329--2335",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "8",

}

TY - JOUR

T1 - Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells

AU - Woo, Yanghee

AU - Kelly, Kaitlyn J.

AU - Stanford, Marianne M.

AU - Galanis, Charles

AU - Shin Chun, Yun

AU - Fong, Yuman

AU - McFadden, Douglas

PY - 2008/8/1

Y1 - 2008/8/1

N2 - Background: Viral oncolytic therapy, which seeks to exploit the use of live viruses to treat cancer, has shown promise in the treatment of cancers resistant to conventional anticancer therapies. Among the most difficult to treat cancers is advanced pancreatic adenocarcinoma. Our study investigates the ability of a novel oncolytic agent, myxoma virus, to infect, productively replicate in, and kill human pancreatic cancer cells in vitro. Methods: The myxoma virus vMyxgfp was tested against a panel of human pancreatic adenocarcinoma cell lines. Infectivity, viral proliferation, and tumor cell kill were assessed. Results: Infection of tumor cells was assessed by expression of the marker gene enhanced green fluorescent protein (e-GFP). vMyxgfp had the ability to infect all pancreatic cancer cell lines tested. Killing of tumor cells varied among the 6 cell lines tested, ranging from >90% cell kill at 7 days for the most sensitive Panc-1 cells, to 39% in the most resistant cell line Capan-2. Sensitivity correlated to replication of virus, and was found to maximally exhibit a four-log increase in foci-forming units for the most sensitive Panc-1 cells within 72 h. Conclusion: Our study demonstrates for the first time the ability of the myxoma virus to productively infect, replicate in, and lyse human pancreatic adenocarcinoma cells in vitro. These data encourage further investigation of this virus, which is pathogenic only in rabbits, for treatment of this nearly uniformly fatal cancer.

AB - Background: Viral oncolytic therapy, which seeks to exploit the use of live viruses to treat cancer, has shown promise in the treatment of cancers resistant to conventional anticancer therapies. Among the most difficult to treat cancers is advanced pancreatic adenocarcinoma. Our study investigates the ability of a novel oncolytic agent, myxoma virus, to infect, productively replicate in, and kill human pancreatic cancer cells in vitro. Methods: The myxoma virus vMyxgfp was tested against a panel of human pancreatic adenocarcinoma cell lines. Infectivity, viral proliferation, and tumor cell kill were assessed. Results: Infection of tumor cells was assessed by expression of the marker gene enhanced green fluorescent protein (e-GFP). vMyxgfp had the ability to infect all pancreatic cancer cell lines tested. Killing of tumor cells varied among the 6 cell lines tested, ranging from >90% cell kill at 7 days for the most sensitive Panc-1 cells, to 39% in the most resistant cell line Capan-2. Sensitivity correlated to replication of virus, and was found to maximally exhibit a four-log increase in foci-forming units for the most sensitive Panc-1 cells within 72 h. Conclusion: Our study demonstrates for the first time the ability of the myxoma virus to productively infect, replicate in, and lyse human pancreatic adenocarcinoma cells in vitro. These data encourage further investigation of this virus, which is pathogenic only in rabbits, for treatment of this nearly uniformly fatal cancer.

KW - In vitro

KW - Myxoma virus

KW - Oncolytic therapy

KW - Pancreatic cancer

KW - Viral vectors

UR - http://www.scopus.com/inward/record.url?scp=48149085568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48149085568&partnerID=8YFLogxK

U2 - 10.1245/s10434-008-9924-z

DO - 10.1245/s10434-008-9924-z

M3 - Article

C2 - 18454298

AN - SCOPUS:48149085568

VL - 15

SP - 2329

EP - 2335

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 8

ER -